Skip to main content
UniHealth

Doctor search

Timothy Minh-Tien Dang, MD

Dermatology · San Diego

NPI 1518427913

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
5

Offices

5 locations · Regents of the University of California · 2,047 clinicians in this group

Looking this up.

Hospitals listed: UC San Diego Health Hillcrest - Hillcrest Med Ctr. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Dang’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A186246 · Current

Licensed to practise in California · since 2023 · expires 2027-05-31 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UC San Diego Health Hillcrest - Hillcrest Med CtrSan Diego, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Moores Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 105.39 (74.34 to 136.44) · 381 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.597, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.618, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.376, Oct 2024 – Sep 2025
See every measure and the patient survey for UC San Diego Health Hillcrest - Hillcrest Med Ctr

Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UC San Diego Health Hillcrest - Hillcrest Med Ctr
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths105.39 (74.34 to 136.44) · 381 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.597BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.618BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.375BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.376BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.83 (0.11 to 1.54) · 3,862 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.02 (0.84 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.4 · 130 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.2 · 116 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.1 · 183 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths7.8 · 510 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths11 · 696 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.4 · 435 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 5,739 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.15 (0 to 0.32) · 12,387 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.1 to 0.44) · 13,596 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.59 (3.24 to 5.94) · 4,389 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.04 (0 to 2.12) · 2,419 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.26 (1.23 to 3.29) · 4,116 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths9.93 (6.61 to 13.25) · 2,232 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.31 (5.24 to 9.38) · 2,410 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.32 (1.07 to 3.56) · 1,286 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.38 (0.02 to 0.75) · 11,838 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.5 · 181 casesNoneApr 2023 – Mar 2025
MRSA BacteremiaInfections0.716No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.672No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.5 · 302 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.3 · 891 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits3.8 · 216 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits5.9 · 620 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits12 · 731 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.7 · 946 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.9 (4.8 to 7) · 1,507 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.3 (10.7 to 14) · 1,507 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits7.1 · 191 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.7 · 177 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.7 · 204 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits10.4 (8.5 to 13) · 4,116 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1) · 2,130 casesNo differentJan 2024 – Dec 2024

What patients said (3,680 patients answered, 16% of those asked)

Patient survey stars by topic at UC San Diego Health Hillcrest - Hillcrest Med Ctr
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital4
Share of patients giving the best answer at UC San Diego Health Hillcrest - Hillcrest Med Ctr
Room was "always" clean66%
Nurses "always" communicated well79%
Doctors "always" communicated well79%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand75%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)73%
Staff "always" explained new medications73%
Nurses "always" explained things so they could understand75%
Nurses "always" listened carefully75%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night49%
"YES", patients would definitely recommend the hospital75%
Staff "always" explained possible side effects48%
Yes, staff "did" give patients information about possible symptoms88%

Original Medicare doctor bills

$130,915

Medicare paid this office $130,915 for 560 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)209$28,890$100
Destruction of skin growth, 1-14 growths108$11,715$93
Return visit (30+ min)74$9,074$74
Short return visit (20+ min)106$8,767$71
New patient visit (45+ min)70$8,538$122
See all 26 services
Every Original Medicare service billed
Return visit (30+ min)209$28,890$100
Destruction of skin growth, 1-14 growths108$11,715$93
Return visit (30+ min)74$9,074$74
Short return visit (20+ min)106$8,767$71
New patient visit (45+ min)70$8,538$122
Long return visit (40+ min)38$8,122$116
Destruction of precancer skin growth, 1 growth130$5,773$40
Destruction of precancer skin growth, 15 or more growths36$5,770$137
Biopsy of related skin growth, first growth66$4,766$67
New patient visit (45+ min)47$4,720$100
New patient visit (30+ min)46$3,819$83
Long return visit (40+ min)21$3,512$140
Destruction of precancer skin growth, 2-14 growths101$3,055$6
New patient visit (60+ min)18$2,657$148
Destruction of skin growth, 1-14 growths27$1,986$55
Punch biopsy, first skin growth16$1,746$103
Destruction of precancer skin growth, 1 growth37$1,433$35
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's57$1,350$14
Short return visit (20+ min)19$1,181$51
New patient visit (30+ min)19$1,071$56
Application of ultraviolet light to skin11$880$23
Punch biopsy, first skin growth22$817$37
Biopsy of related skin growth, first growth23$632$26
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's23$392$14
Destruction of precancer skin growth, 2-14 growths29$179$2
Injection, triamcinolone acetonide, not otherwise specified, 10 mg12$15None

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions535More than 87% of doctors who do this
Removal or shaving of skin growth33More than 76% of doctors who do this
Skin biopsy178More than 83% of doctors who do this

Who their Medicare patients are

560 Original Medicare patients in 2024. Average age 74 · Under 65 9% · 85 and older 10% · Women 47% · Also on Medicaid 19% · Health risk score 1.66. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 64% · Cancer 28% · Coronary heart disease 25% · Depression 24% · Chronic kidney disease 22% · Diabetes 19% · Atrial fibrillation 18% · COPD 15% · Heart failure 14% · Stroke 6% · Dementia 5%.

The office billed $660,979, Medicare allowed $177,260 and paid $130,915; for 2,337 services of 40 kinds; $15 of it was for drugs given in the office and $130,900 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20245602,337741.66$660,979$130,915
2023291886731.41$223,937$53,675

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 11 services

Original Medicare services billed in 2023
Return visit (30+ min)92$11,045$106
New patient visit (45+ min)62$8,592$139
Destruction of skin growth, 1-14 growths50$5,293$102
Short return visit (20+ min)58$4,555$77
New patient visit (30+ min)48$4,055$84
Biopsy of related skin growth, first growth43$3,622$80
Destruction of precancer skin growth, 1 growth68$3,156$45
Destruction of precancer skin growth, 2-14 growths53$1,610$6
Return visit (30+ min)19$1,610$80
Punch biopsy, first skin growth13$1,474$113
Biopsy of related skin growth, each additional growth14$919$44

Medicaid work

$377 in 2023

Medicaid paid $377 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
Return visit (30+ min)12$377
Medicaid work by year
202312112$377

Drugs they prescribed that Part D paid

$1,223,938

Pharmacies billed $1,223,938 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,483) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

1,258 generic and 225 brand-name prescriptions · $1,223,938 in drug cost · 65 antibiotic prescriptions to 30 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Dupixent93$345,678$3,717
Skyrizi17$319,577$18,799
Humira(Cf)12$144,026$12,002
Otezla29$112,776$3,889
Opzelura11$26,208$2,383
See all 30 drugs
Every Part D drug this clinician prescribed
Dupixent93$345,678$3,717
Skyrizi17$319,577$18,799
Humira(Cf)12$144,026$12,002
Otezla29$112,776$3,889
Opzelura11$26,208$2,383
Zoryve13$10,844$834
Acitretin17$10,092$594
Clobetasol Propionate119$5,518$46
Tacrolimus38$5,117$135
Tazarotene14$4,600$329
Fluorouracil56$3,426$61
Fluocinonide80$2,514$31
Ketoconazole169$2,383$14
Triamcinolone Acetonide159$1,954$12
Metronidazole23$1,283$56
Betamethasone Diprop Augmented28$1,101$39
Doxycycline Hyclate46$886$19
Clindamycin Phosphate32$865$27
Ciclopirox25$826$33
Dexamethasone22$576$26
Pilocarpine12$564$47
Mupirocin97$545$6
Clotrimazole19$397$21
Imiquimod18$329$18
Econazole Nitrate15$296$20
Hydrocortisone71$252$4
Minoxidil19$220$12
Valacyclovir11$198$18
Fluconazole17$155$9
Prednisone16$110$7

Year by year

Part D prescribing by year
20241,4834010% (0)15%$1,223,938
20235062260% (0)9%$211,603
2022209990% (0)10%$18,509
2021161830% (0)12%$10,369
202080500% (0)19%$4,030

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 15 drugs

Part D drugs prescribed in 2023
Otezla12$58,922$4,910
Tacrolimus15$3,326$222
Clobetasol Propionate35$2,657$76
Ketoconazole59$1,308$22
Fluorouracil16$1,249$78
Triamcinolone Acetonide56$979$17
Fluocinonide18$889$49
Doxycycline Monohydrate12$876$73
Clindamycin Phosphate14$825$59
Betamethasone Diprop Augmented18$790$44
Ciclopirox19$630$33
Hydrocortisone29$255$9
Mupirocin32$245$8
Doxycycline Hyclate11$227$21
Valacyclovir13$161$12

2022: 3 drugs

Part D drugs prescribed in 2022
Betamethasone Diprop Augmented27$1,823$68
Ketoconazole26$673$26
Triamcinolone Acetonide36$635$18

2021: 4 drugs

Part D drugs prescribed in 2021
Clobetasol Propionate14$1,683$120
Triamcinolone Acetonide24$328$14
Ketoconazole16$326$20
Methotrexate13$316$24

2020: 1 drug

Part D drugs prescribed in 2020
Triamcinolone Acetonide11$176$16

Money from drug and device companies

$901 in 2025

Industry payments by year
2025610None$901
202423None$275
202366None$694
202211None$125

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Galderma Laboratories L.P.Nemluvio$386
3 payments
  • Meals for Nemluvio · 2025-12-16 · $144
  • Meals for Nemluvio · 2025-04-30 · $106
  • Meals for Nemluvio · 2025-02-18 · $136
Regeneron PharmaceuticalsLibtayo$149
1 payment
  • Meals for Libtayo · 2025-11-19 · $149
E.R. Squibb & Sons L.L.C.Sotyktu$124
3 payments
  • Meals for Sotyktu · 2025-07-31 · $23
  • Meals for Sotyktu · 2025-07-29 · $52
  • Meals for Sotyktu · 2025-04-10 · $49
AbbvieSkyrizi$115
1 payment
  • Meals for Skyrizi · 2025-01-08 · $115
MedtronicInceptiv$105
1 payment
  • Meals for Inceptiv · 2025-10-02 · $105
Abbott LaboratoriesEterna$22
1 payment
  • Meals for Eterna · 2025-12-09 · $22
See all 10 published payments
Every published payment
Galderma Laboratories L.P.Meals · 2025-12-16Nemluvio$144
Abbott LaboratoriesMeals · 2025-12-09Eterna$22
Regeneron PharmaceuticalsMeals · 2025-11-19Libtayo$149
MedtronicMeals · 2025-10-02Inceptiv$105
E.R. Squibb & Sons L.L.C.Meals · 2025-07-31Sotyktu$23
E.R. Squibb & Sons L.L.C.Meals · 2025-07-29Sotyktu$52
Galderma Laboratories L.P.Meals · 2025-04-30Nemluvio$106
E.R. Squibb & Sons L.L.C.Meals · 2025-04-10Sotyktu$49
Galderma Laboratories L.P.Meals · 2025-02-18Nemluvio$136
AbbvieMeals · 2025-01-08Skyrizi$115
See earlier years (2024, 2023, 2022)

2024: $275

Payments by company in 2024
Abbott LaboratoriesEterna$145
1 payment
  • Meals for Eterna · 2024-12-12 · $145
Regeneron PharmaceuticalsLibtayo$130
2 payments
  • Meals for Libtayo · 2024-11-21 · $76
  • Meals for Libtayo · 2024-11-07 · $54

2023: $694

Payments by company in 2023
Dermavant SciencesVtama$148
1 payment
  • Meals for Vtama · 2023-03-08 · $148
Galderma Laboratories L.P.None$134
1 payment
  • Meals · 2023-05-04 · $134
AbbVieRinvoq$124
1 payment
  • Meals for Rinvoq · 2023-03-07 · $124
Regeneron PharmaceuticalsLibtayo$109
1 payment
  • Meals for Libtayo · 2023-12-15 · $109
Janssen BiotechTremfya$95
1 payment
  • Education for Tremfya · 2023-09-18 · $95
Boehringer Ingelheim PharmaceuticalsNone$83
1 payment
  • Meals · 2023-03-18 · $83

2022: $125

Payments by company in 2022
Boehringer Ingelheim PharmaceuticalsNone$125
1 payment
  • Meals · 2022-11-16 · $125

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Regeneron Pharmaceuticals, Inc. · A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (Cscc) · 2025This clinician$2,191

Professional record

NPI
1518427913
Licence
CA A186246California A186246: Current · expires 2027-05-31
Trained
Stanford University School of Medicine, 2019
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X); Student in a training program (390200000X)
Mailing address
File 57326, Los Angeles, CA, 90074
NPI first listed
2019-03-21
NPI last updated
2024-04-11
NPI record certified
2024-04-11

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 55 Fruit St, Boston, MA, 02114 · 3855 Health Sciences Dr, La Jolla, CA, 92093 · 8899 University Center Ln, San Diego, CA, 92122 · 751 S Bascom Ave, San Jose, CA, 95128